Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Limited-stage mantle-cell lymphoma.

H A Leitch1, R D Gascoyne, M Chhanabhai

  • 1Division of Medical Oncology, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|September 25, 2003
PubMed
Summary

Limited-stage mantle cell lymphoma (MCL) patients treated with radiation therapy (RT) showed improved progression-free survival. RT appears to be a crucial component in managing limited-stage MCL, potentially improving outcomes for all age groups.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The 2022 ITAC evidence-based clinical practice guidelines: New update from the International Initiative on Thrombosis and Cancer to improve the care in patients with cancer-associated thrombosis.

Journal de medecine vasculaire·2022
Same author

Cancer and thrombosis: new insights to an old problem.

Journal de medecine vasculaire·2020
Same author

Association between D-Dimer levels and mortality in patients with coronavirus disease 2019 (COVID-19): a systematic review and pooled analysis.

Journal de medecine vasculaire·2020
Same author

New progress in the treatment and prophylaxis of venous thrombo-embolism in cancer patients.

Journal de medecine vasculaire·2020
Same author

An MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic scoring.

Leukemia·2019
Same author

Hodgkin lymphoma, treatment and thrombosis: a dangerous mix.

Annals of oncology : official journal of the European Society for Medical Oncology·2019

Area of Science:

  • Oncology
  • Hematology
  • Clinical Research

Background:

  • Mantle cell lymphoma (MCL) typically presents with advanced disease and has a poor prognosis.
  • Limited information exists regarding the optimal management and outcomes for patients with limited-stage MCL.

Purpose of the Study:

  • To evaluate the outcomes of patients diagnosed with limited-stage mantle cell lymphoma.
  • To determine the impact of different treatment modalities, including radiation therapy (RT) and chemotherapy (CT), on progression-free survival (PFS) and overall survival (OS).

Main Methods:

  • Retrospective review of clinicopathological data for patients with limited-stage MCL.
  • Analysis of treatment regimens, including involved-field radiation therapy (RT) with or without chemotherapy (CT), chemotherapy alone, or observation.

Related Experiment Videos

  • Assessment of progression-free survival (PFS) and overall survival (OS) based on patient demographics and treatment received.

    • Main Results:

    • Twenty-six patients with low-bulk, stage IA or IIA MCL were identified.
    • Patients treated with RT (with or without CT) demonstrated significantly improved 5-year PFS (68%) compared to those not receiving RT (11%).
    • Initial RT also appeared to mitigate the negative impact of age on PFS, with a trend towards improved OS.

    Conclusions:

    • Treatment regimens incorporating radiation therapy (RT) are associated with improved progression-free survival (PFS) in limited-stage mantle cell lymphoma (MCL).
    • Radiation therapy may play a significant role in improving outcomes for patients with limited-stage MCL.
    • Further investigation into the role of RT in limited-stage MCL is warranted.